S&P 500   5,006.78 (-0.31%)
DOW   37,724.92 (-0.08%)
QQQ   423.77 (-0.49%)
AAPL   166.92 (-0.64%)
MSFT   406.13 (-1.39%)
META   504.64 (+2.12%)
GOOGL   156.42 (+0.61%)
AMZN   179.13 (-1.19%)
TSLA   150.12 (-3.43%)
NVDA   845.63 (+0.63%)
AMD   154.35 (+0.21%)
NIO   4.01 (+2.56%)
BABA   68.89 (+0.10%)
T   16.22 (+0.62%)
F   12.00 (-0.33%)
MU   113.06 (-2.81%)
GE   154.28 (-0.89%)
CGC   7.96 (+22.65%)
DIS   112.79 (-0.13%)
AMC   2.91 (-2.35%)
PFE   25.32 (-0.39%)
PYPL   62.12 (-1.80%)
XOM   118.11 (-0.44%)
S&P 500   5,006.78 (-0.31%)
DOW   37,724.92 (-0.08%)
QQQ   423.77 (-0.49%)
AAPL   166.92 (-0.64%)
MSFT   406.13 (-1.39%)
META   504.64 (+2.12%)
GOOGL   156.42 (+0.61%)
AMZN   179.13 (-1.19%)
TSLA   150.12 (-3.43%)
NVDA   845.63 (+0.63%)
AMD   154.35 (+0.21%)
NIO   4.01 (+2.56%)
BABA   68.89 (+0.10%)
T   16.22 (+0.62%)
F   12.00 (-0.33%)
MU   113.06 (-2.81%)
GE   154.28 (-0.89%)
CGC   7.96 (+22.65%)
DIS   112.79 (-0.13%)
AMC   2.91 (-2.35%)
PFE   25.32 (-0.39%)
PYPL   62.12 (-1.80%)
XOM   118.11 (-0.44%)
S&P 500   5,006.78 (-0.31%)
DOW   37,724.92 (-0.08%)
QQQ   423.77 (-0.49%)
AAPL   166.92 (-0.64%)
MSFT   406.13 (-1.39%)
META   504.64 (+2.12%)
GOOGL   156.42 (+0.61%)
AMZN   179.13 (-1.19%)
TSLA   150.12 (-3.43%)
NVDA   845.63 (+0.63%)
AMD   154.35 (+0.21%)
NIO   4.01 (+2.56%)
BABA   68.89 (+0.10%)
T   16.22 (+0.62%)
F   12.00 (-0.33%)
MU   113.06 (-2.81%)
GE   154.28 (-0.89%)
CGC   7.96 (+22.65%)
DIS   112.79 (-0.13%)
AMC   2.91 (-2.35%)
PFE   25.32 (-0.39%)
PYPL   62.12 (-1.80%)
XOM   118.11 (-0.44%)
S&P 500   5,006.78 (-0.31%)
DOW   37,724.92 (-0.08%)
QQQ   423.77 (-0.49%)
AAPL   166.92 (-0.64%)
MSFT   406.13 (-1.39%)
META   504.64 (+2.12%)
GOOGL   156.42 (+0.61%)
AMZN   179.13 (-1.19%)
TSLA   150.12 (-3.43%)
NVDA   845.63 (+0.63%)
AMD   154.35 (+0.21%)
NIO   4.01 (+2.56%)
BABA   68.89 (+0.10%)
T   16.22 (+0.62%)
F   12.00 (-0.33%)
MU   113.06 (-2.81%)
GE   154.28 (-0.89%)
CGC   7.96 (+22.65%)
DIS   112.79 (-0.13%)
AMC   2.91 (-2.35%)
PFE   25.32 (-0.39%)
PYPL   62.12 (-1.80%)
XOM   118.11 (-0.44%)

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
$15.98
+5.5%
$17.55
$8.92
$24.50
$723.89M1.67401,754 shs333,176 shs
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
$86.67
-1.4%
$83.01
$36.42
$99.63
$2.83B1.99685,718 shs459,949 shs
ViewRay, Inc. stock logo
VRAY
ViewRay
$0.34
$0.02
$4.96
$4.59M0.817.51 million shs108.50 million shs
(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
-5.38%-12.28%-10.94%-11.10%-23.15%
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
-5.84%-8.14%+18.47%+9.46%+23.42%
ViewRay, Inc. stock logo
VRAY
ViewRay
0.00%0.00%0.00%0.00%-97.95%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
1.9109 of 5 stars
3.51.00.00.02.62.50.6
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
0.7696 of 5 stars
2.41.00.00.01.92.50.6
ViewRay, Inc. stock logo
VRAY
ViewRay
1.5179 of 5 stars
3.00.00.04.40.01.70.0

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
3.00
Buy$23.4046.43% Upside
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
2.86
Moderate Buy$102.0017.69% Upside
ViewRay, Inc. stock logo
VRAY
ViewRay
2.00
Hold$1.33∞ Upside

Current Analyst Ratings

Latest BLFS, VRAY, and TMDX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/4/2024
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$22.00
3/28/2024
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$95.00
2/28/2024
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$75.00 ➝ $95.00
2/27/2024
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$87.00 ➝ $105.00
2/27/2024
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$92.00 ➝ $105.00
(Data available from 4/18/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
$143.27M5.05N/AN/A$7.67 per share2.08
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
$241.62M11.73$0.13 per share655.55$4.20 per share20.64
ViewRay, Inc. stock logo
VRAY
ViewRay
$105.86M0.00N/AN/A$0.45 per share0.00

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
-$66.43M-$1.52N/AN/AN/A-46.37%-13.36%-10.83%5/8/2024 (Estimated)
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
-$25.03M-$0.77N/A211.39N/A-10.36%-2.35%-0.60%4/30/2024 (Confirmed)
ViewRay, Inc. stock logo
VRAY
ViewRay
-$107.33M-$0.60N/AN/AN/A-104.30%-120.48%-42.39%N/A

Latest BLFS, VRAY, and TMDX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
4/30/2024N/A
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
-$0.05N/A+$0.05N/AN/AN/A  
2/29/2024Q4 2023
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
-$0.24-$0.22+$0.02-$0.14$32.70 million$32.73 million
2/26/2024Q4 2023
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
-$0.10$0.12+$0.22$0.12$68.49 million$81.20 million    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
N/AN/AN/AN/AN/A
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
N/AN/AN/AN/AN/A
ViewRay, Inc. stock logo
VRAY
ViewRay
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
0.06
2.86
1.83
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
3.69
9.30
8.49
ViewRay, Inc. stock logo
VRAY
ViewRay
N/A
1.16
0.91

Ownership

Institutional Ownership

CompanyInstitutional Ownership
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
93.24%
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
99.67%
ViewRay, Inc. stock logo
VRAY
ViewRay
92.97%

Insider Ownership

CompanyInsider Ownership
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
2.70%
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
6.70%
ViewRay, Inc. stock logo
VRAY
ViewRay
2.50%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
40945.30 million44.08 millionOptionable
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
58432.71 million30.52 millionOptionable
ViewRay, Inc. stock logo
VRAY
ViewRay
295183.40 million178.82 millionOptionable

BLFS, VRAY, and TMDX Headlines

SourceHeadline
The best 4K Blu-ray players for 2024The best 4K Blu-ray players for 2024
digitaltrends.com - March 24 at 6:22 PM
VRAY Jan 2025 2.000 callVRAY Jan 2025 2.000 call
finance.yahoo.com - March 16 at 9:28 AM
VRAY Jan 2025 0.500 putVRAY Jan 2025 0.500 put
finance.yahoo.com - March 16 at 9:28 AM
VRAY Jan 2025 0.500 callVRAY Jan 2025 0.500 call
finance.yahoo.com - March 16 at 12:50 AM
VRAY Jan 2025 3.000 putVRAY Jan 2025 3.000 put
finance.yahoo.com - March 16 at 12:50 AM
Creating the Scene with V-Ray for 3ds MaxCreating the Scene with V-Ray for 3ds Max
archdaily.com - March 2 at 1:34 PM
How to Supercharge Your SketchUp Renders With V-Ray Lights and MaterialsHow to Supercharge Your SketchUp Renders With V-Ray Lights and Materials
archdaily.com - February 26 at 6:18 PM
ViewRay Inc VRAYQViewRay Inc VRAYQ
morningstar.com - November 4 at 7:06 AM
NUBURU Appoints Brian Knaley as new CEONUBURU Appoints Brian Knaley as new CEO
benzinga.com - November 1 at 5:27 PM
Open Letter to ViewRay Customers, Service, Software Engineers and Suppliers-Lets Preserve ViewRay TechnologyOpen Letter to ViewRay Customers, Service, Software Engineers and Suppliers-Let's Preserve ViewRay Technology
tmcnet.com - October 19 at 8:02 AM
Letter to ViewRay Lenders/Investment Bankers and Customers From Krishnan Suthanthiran, President/Founder of TeamBest Global CompaniesLetter to ViewRay Lenders/Investment Bankers and Customers From Krishnan Suthanthiran, President/Founder of TeamBest Global Companies
benzinga.com - October 17 at 1:37 PM
ViewRay Inc (6L9.BE)ViewRay Inc (6L9.BE)
ca.finance.yahoo.com - August 20 at 6:13 PM
B. Riley Securities downgrades ViewRay Inc. (VRAY) rating to a NeutralB. Riley Securities downgrades ViewRay Inc. (VRAY) rating to a Neutral
knoxdaily.com - July 24 at 3:24 PM
ViewRay stock to be delisted from Nasdaq and moved to OTC ExchangeViewRay stock to be delisted from Nasdaq and moved to OTC Exchange
seekingalpha.com - July 21 at 6:20 PM
ViewRay® Announces Commencement of Nasdaq Delisting Proceedings: Common Stock Expected to Begin Trading on the OTC MarketsViewRay® Announces Commencement of Nasdaq Delisting Proceedings: Common Stock Expected to Begin Trading on the OTC Markets
finance.yahoo.com - July 21 at 6:20 PM
Keeping an Eye on ViewRay Inc. (VRAY) After Insider Trading ActivityKeeping an Eye on ViewRay Inc. (VRAY) After Insider Trading Activity
knoxdaily.com - July 19 at 1:18 PM
Why ViewRay Stock Hit A New 52-Week Low TodayWhy ViewRay Stock Hit A New 52-Week Low Today
benzinga.com - July 18 at 8:33 PM
ViewRay, Inc.: ViewRay Files Voluntary Chapter 11 PetitionsViewRay, Inc.: ViewRay Files Voluntary Chapter 11 Petitions
finanznachrichten.de - July 18 at 10:32 AM
Why ViewRay (VRAY) Stock Hit A New 52-Week Low TodayWhy ViewRay (VRAY) Stock Hit A New 52-Week Low Today
msn.com - July 17 at 1:15 PM
Why Is ViewRay (VRAY) Stock Down 69% Today?Why Is ViewRay (VRAY) Stock Down 69% Today?
investorplace.com - July 17 at 12:04 PM
ViewRay® Files Voluntary Chapter 11 PetitionsViewRay® Files Voluntary Chapter 11 Petitions
finance.yahoo.com - July 17 at 8:15 AM
ViewRay Inc. (VRAY) may enjoy gains as insiders got busy in the recent daysViewRay Inc. (VRAY) may enjoy gains as insiders got busy in the recent days
knoxdaily.com - July 12 at 5:59 PM
ViewRay: Near-Term Bankruptcy Filing Might Be In The Cards - SellViewRay: Near-Term Bankruptcy Filing Might Be In The Cards - Sell
msn.com - July 7 at 9:16 AM
Analyzing ViewRay Inc. (VRAY) After Recent Trading ActivityAnalyzing ViewRay Inc. (VRAY) After Recent Trading Activity
knoxdaily.com - July 5 at 8:52 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

BioLife Solutions logo

BioLife Solutions

NASDAQ:BLFS
BioLife Solutions, Inc. develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction tools, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; and the ThawSTAR line that comprises of a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. The company also provides cryogenic freezer technology for controlled rate freezing and cryogenic storage of biologic materials; ultra-low temperature mechanical freezers; evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage and transport services. It markets and sells its products directly, as well as through third party distributors. The company was incorporated in 1987 and is headquartered in Bothell, Washington.
TransMedics Group logo

TransMedics Group

NASDAQ:TMDX
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
ViewRay logo

ViewRay

NASDAQ:VRAY
ViewRay, Inc. designs, manufactures, and markets magnetic resonance imaging (MRI) guided radiation therapy systems to image and treat cancer patients in the United States, Italy, France, Taiwan, the United Kingdom, and internationally. It provides MRIdian, which is an MRI guided radiation therapy system that addresses beam distortion, skin toxicity, and other concerns. The company serves university research and teaching hospitals, community hospitals, private practices, government institutions, and freestanding cancer centers through a network of direct sales force and distributors. ViewRay, Inc. was founded in 2004 and is headquartered in Denver, Colorado.